CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of non-small cell lung cancer (NSCLC).
  
  LEARNING OBJECTIVES

  • Assess the anticipated benefits, risks and long-term outcomes associated with the use of adjuvant and neoadjuvant therapy in the management of Stage IB to IIIA non-small cell lung cancer (NSCLC), and consider this information when counseling patients regarding current therapeutic recommendations.
  • Evaluate available data documenting the efficacy and safety of anti-PD-1/PD-L1 antibodies, and appropriately identify patients who may benefit from adjuvant or neoadjuvant immune checkpoint inhibition.
  • Appreciate emerging Phase III findings with the use of an anti-PD-L1 antibody after the completion of chemotherapy and surgery for patients with resectable NSCLC, and consider the potential effect of this information on current and future clinical practice.
  • Evaluate the clinical relevance of the various genomic abnormalities found in patients with localized NSCLC, and appreciate available and emerging data attempting to validate the efficacy of targeted therapy in these individuals.
  • Recall the design of ongoing clinical trials evaluating immune checkpoint inhibitor therapy for patients with localized NSCLC, and counsel appropriate patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Edward B Garon, MD, MS
  Professor
  Director, Thoracic Oncology Program
  Director, Signal Transduction and Therapeutics Research Program
  David Geffen School of Medicine at UCLA
  Jonsson Comprehensive Cancer Center
  Los Angeles, California
  
  Consulting Agreements: ABL Bio, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Dracen Pharmaceuticals, Eisai Inc, EMD Serono Inc, GlaxoSmithKline, Merck, Natera Inc, Novartis, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Shionogi Inc, Xilio Therapeutics; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Dynavax Technologies, EMD Serono Inc, Genentech, a member of the Roche Group, Iovance Biotherapeutics, Lilly, Merck, Mirati Therapeutics, Neon Therapeutics, Novartis.
  
  Jarushka Naidoo, MB BCH, MHS
  Consultant Medical Oncologist
  Beaumont Hospital
  Dublin, Ireland
  Adjunct Assistant Professor of Oncology
  Johns Hopkins University
  Baltimore, Maryland
  
  Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Merck, Pfizer Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Merck; Data and Safety Monitoring Board/Committee: Daiichi Sankyo Inc.
  
  Harvey I Pass, MD
  Stephen E Banner Professor of Thoracic Oncology
  Vice-Chairman, Research
  Department of Cardiothoracic Surgery
  Director, General Thoracic Surgery
  NYU Langone Medical Center
  New York, New York
  
  No relevant conflicts of interest to disclose
  
  Heather Wakelee, MD
  Professor of Medicine
  Chief, Division of Oncology
  Stanford University School of Medicine
  Deputy Director, Stanford Cancer Institute
  Stanford, California
  
  Advisory Board (Compensated): AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Daiichi Sankyo Inc, Helsinn Healthcare SA, Janssen Biotech Inc, Mirati Therapeutics, Xcovery; Advisory Board (Not Compensated): Cellworks, Genentech, a member of the Roche Group, Merck, Takeda Oncology; Research Funding to Institution: ACEA Biosciences Inc, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics,AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Merck, Novartis, Pharmacyclics LLC, an AbbVie Company, Seagen Inc, Xcovery.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  These activities are supported by an educational grant from Genentech, a member of the Roche Group.
  
  Release date: October 2021
  Expiration date: October 2022